Senior researcher
+420 495 832 502
Rafael.Dolezal@fnhk.cz
ORCID: 0000-0001-9495-3934
Rafael received his Ph.D. at the Faculty of Pharmacy (Charles University) in Hradec Kralove in 2008. The dissertation thesis was focused on exploring the quantitative structure-activity relationships (QSAR) of potential drugs against tuberculosis with the use of quantum chemistry computational methods. During his second Ph.D. studies in Applied Informatics (FIM UHK), he focused on developing innovative in silico drug design methods using supercomputing technologies. He also worked on processing biomedical data (WCE, MRI, EEG, ECG, EMG, etc.) using massively parallelized machine learning and artificial intelligence methods. He currently serves as a senior researcher at the Biomedical Research Center (BRC) at the University Hospital Hradec Králové. He is involved in the development and testing of new drugs against Alzheimer’s disease, de novo determination of chemical structures using LC-MS/MS methods, and the early-stage diagnosis of neurological and oncological diseases.
| Assoc. Prof. | (2020) | Charles University in Prague, Faculty of Pharmacy, Czech Republic, field of expertise: Medicinal Chemistry |
| Ph.D. | (2008) | Charles University in Prague, Faculty of Pharmacy, Department of Inorganic and Organic Chemistry, field of study: Bioorganic Chemistry |
| Dissertation thesis title: “Quantitative structure-antimycobacterial acitivity relationships in the group of potential antituberculotics” |
Drug design, bioanalytical studies, analyses of biomedical data
| 2015 - now | Senior researcher, Biomedical Research Center (BRC), University Hospital Hradec Kralove |
| 2012 - 2015 | Post-Doc, Analytical chemistry, Biomedical Research Center (BRC), University Hospital Hradec Kralove |
| 2004 - 2008 | Ph.D. student, Department of Inorganic and Organic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague |
| 2-6/2006 | Ghent University (Belgium), Department of Inorganic and Physical chemistry (5 months) |
| Title: | Application of molecular modeling to research of the relationships between structure and biological activity of organic compounds |
| Funding: | Higher Education Development Fund, FRVŠ no. 946/2006 |
| Schedule: | 2006 |
| Role: | primary investigator |
| 2006 - 2007 | Teaching of Organic chemistry and Biological activity seminars |
(dated 11/2013)
Sepsova, V., Karasova, J. Z., Korabecny, J., Dolezal, R., Zemek, F., Bennion, B. J., Kuca, K.: Oximes: Inhibitors of Human Recombinant Acetylcholinesterase. A Structure-Activity Relationship (SAR) Study. Int. J. Mol. Sci. 2013, 14(8), 16882-16900.
Korabecny, J., Janovec, L., Musilek, K., Zemek, F., Horova, A., Nepovimova, E., Dolezal, R., Opletalova, V., Hroudova, J., Fisar, Z., Jung, Y. S., Kuca, K.: Comparison of Novel Tacrine and 7-MEOTA Derivatives with Aromatic and Alicyclic Residues: Synthesis, Biological Evaluation and Docking Studies. Lett. Org. Chem. 2013, 10(4), 291-297.
Petrlíková, E., Waisser K., Doležal, R., Holý, P., Gregor, J., Kuneš, J., Kaustová J.: Antimycobacterial 3-phenyl-4-thioxo-2H-1,3-benzoxazine-2(3H)-ones and 3-phenyl-2H-1,3-benzoxazine-2,4(3H)-dithiones substituted on phenyl and benzoxazine moiety in position 6. Chem. Pap. 2011, 65 (3), 352-366.
Nesměrák K., Doležal R., Hudská V., Bártl J., Štícha M., Waisser K.: Quantitative Structure–Electrochemistry Relationship of 1-Phenyl-5-benzyl-sulfanyltetrazoles and Their Electrooxidation as a Metabolic Model. Electroanalysis 2010, 22(17-18), 2117–2122.
Doležal, R., Waisser, K., Petrlíková, E., Kuneš, J., Kubicová, L., Macháček, M., Kaustová, J.,Dahse H. M.: N-Benzylsalicylthioamides: Highly Active Potential Antituberculotics. Arch. Pharm. Life Sci. 2009, 342, 113-119.
Doležal, R., Van Damme, S., Bultinck, P., Waisser, K.: QSAR analysis of salicylamide isosteres with the use of quantum chemical molecular descriptors. Eur. J. Med. Chem. 2009, 44(2), 869-876.
Waisser K., Matyk J., Kuneš J., Doležal R., Kaustová J., Dahse H. M.: Highly aktive potential antituberculotics: 3-(4-alkyl)phenyl-4-thioxo-2H-1,3-benzoxazine-2(3H)-ones and 3-(4-alkylphenyl)-2H-1,3-benzoxazine-2,4(3H)-dithiones substituted in ring B by halogen. Arch. Pharm. Life Sci. 2008, 341, 800-803.
